of proteins. * There are some who feel that the virulence of MRSA has been greatly exaggerated. We do not fully understand the nature of virulence in S. aureus. It is likely to be an interaction of many seed factors within a soil of varying susceptibility and exposed to different or changing climatic conditions. Lacey and co-worker~~ discussed their experience with an MRSA of low virulence on a bums unit. That strain was unusual in that it lacked lipase and was a weak producer of clumping (slide coagulase) factor and protein A, all purported virulence factors. Virulence factors linked with phagelo have been found in a strain circulating in the UK (the so-called " EMRSA-1 ") and in epidemic MRSA from eastem Australiall and may thus be expected to vary between, or even during, MRSA outbreaks. However, we cannot provide reliable predictors of virulence in the laboratory. Although several units have experienced outbreaks similar to that described by Lacey et al., on other occasions MRSA has caused considerable morbidity and mortality.* Nevertheless, it is interesting that MRSA rarely cause the primary sepsis in healthy staff seen with the infamous 80/81 strain of S. aureus of the 1950s.
Clearly, certain MRSA express epidemic potential, but the identification of reliable laboratory markers has eluded research efforts. Experience would suggest that the answer to this question also lies in the interaction between the seed, the soil and the climate. EMRSA-1 (perhaps the archetypal epidemic MRSA) does not necessarily spread when introduced into a hospital setting.12 We need to know more about the reasons for failure and success of MRSA c o n t r 0 1 .~~~~~ l3 The introduction of new therapeutic agents to treat infections or eradicate carriage of MRSA has resulted, as might have been predicted, in the emergence of resistance. This has occurred with a frightening rapidity in the case of the quinolones and mupirocin. There are clues that some of the resistance genes originated in other bacterial species.14* l5 Glycopeptides remain effective, but the spectre of vancomycin resistance looms large; proposed benefits of using this ageQt prophylactically must be examined very critically? We may be able to draw some comfort from the fact that transfer of vanA produced an unstable tran~conjugant.'~ Some have criticised this kind of experimentation but, provided it is performed in carefully controlled conditions and with appropriate recipients, it provides important information for infection control teams and clinicians of the potential dynamics and control measures which might prevent the emergence of resistance in v i m .
The rationale for control of MRSA has been discussed in several recent articles and guidelines.'! 2r l8 There are differences of opinion about the advisability of attempting to eradicate MRSA with topical or systemic therapy. Several workers have used mupirocin to eradicate MRSA from nasal and wound sites and, in theory, this should reduce MRSA transmission to staff and then to other patients. 19 However, the prophylactic use of mupirocin20 must increase the chance of resistance emerging and, indeed, mupirocin resistance in MRSA, though still rare, has been cases were successful in eradicating MRSA compared to 71 YO with 20-39 cases and 10 % with 2 40 cases. The extent of the control measures depends on the morbidity and mortality caused by the MRSA, the consequences of infection in different patient groups, and the comparative cost of ignoring the MRSA or trying to contain it. It is best to avoid a prescriptive or dogmatic approach; requests for additional infection control resources should be balanced with other
